| Literature DB >> 30934693 |
Siyi He1, Yue Zhao2, Yongsheng Fan3, Xue Zhao4, Jun Yu5, Jie Xie6, Chunhong Wang7, Jianmei Su8.
Abstract
Background: Monocarboxylate transport protein 1 (MCT1) has been defined as a critical regulator in tumor energy metabolism, but bibliometric analysis of MCT1 research is rare. This study aimed to comprehensively analyze the global scientific output of MCT1 research and explore the hotspots and frontiers from the past decade.Entities:
Keywords: CiteSpace; bibliometrics; monocarboxylate transport protein 1; neoplasms
Mesh:
Substances:
Year: 2019 PMID: 30934693 PMCID: PMC6479916 DOI: 10.3390/ijerph16071091
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow diagram of study selection based on PRISMA 2009 guidelines.
Figure 2Changes of the quantity of annual publications on the research of monocarboxylate transport protein 1 (MCT1) indexed in the Web of Science during 2008–2018.
Figure 3Visualization of research field. (Note: The size of a circle is in proportion to the amount of literature of the category, and the thickness of the lines is proportional to the relevance between different areas of research. The colors of rings of a circle are corresponding to the year. The purple rims of circles represent the high betweenness centralities).
Figure 4Visualization of leading countries. The country collaboration network of MCT1 constructed by CiteSpace has been observed with 36 nodes and 140 links, as 851 articles were contributed by 47 countries.
Top 10 most productive institutions that contributed to MCT1 research.
| Rank | Count | Institution | Country | Continent | Research Focus |
|---|---|---|---|---|---|
| 1 | 40 | Univ Minho | Portugal | Europe | Targeting MCT1 as a treatment of cancer. |
| 2 | 34 | Univ Porto | Portugal | Europe | Targeting MCT1 as a treatment of cancer. |
| 3 | 31 | ICVS 3Bs PT Govt Associate Lab | Portugal | Europe | Targeting MCT1 as a treatment of cancer. |
| 4 | 20 | Univ Lausanne | Switzerland | Europe | MCT1 expression related to metabolism |
| 5 | 19 | Hokkaido Univ | Japan | Asia | Immunohistochemical localization and expression of MCT1 |
| 6 | 18 | SUNY Buffalo | USA | North America | Targeting MCT1 as a treatment of GHB Overdose |
| 7 | 18 | Univ Copenhagen | Denmark | Europe | strength training on muscle and MCT1 |
| 8 | 17 | Barretos Canc Hosp | Brazil | South America | MCT1 and anaerobic glycolysis in tumor cells |
| 9 | 14 | Univ Sao Paulo | Brazil | South America | Targeting MCT1 as a treatment of cancer. |
| 10 | 13 | Univ Manchester | England | Europe | MCT1 as functional biomarkers in cancer |
Figure 5Map of the most productive authors contributed to MCT1 research with collaborative links. The author collaboration network of MCT1 constructed by CiteSpace was observed with 225 nodes and 436 links, as 851 articles were contributed by 225 authors. Each node represents an author, and each link reflects the collaboration network.
Top 10 most active authors and co-cited authors contributed to MCT1 research.
| Rank | Author | Country | Count | Co-Cited Author | Country | Citation |
|---|---|---|---|---|---|---|
| 1 | BALTAZAR F | Portugal | 38 | HALESTRAP AP | England | 357 |
| 2 | PINHEIRO C | Portugal | 27 | PINHEIRO C | Portugal | 132 |
| 3 | MORRIS ME | USA | 18 | SONVEAUX P | Belgium | 130 |
| 4 | PELLERIN L | Switzerland | 14 | WILSON MC | England | 118 |
| 5 | SONVEAUX P | Belgium | 14 | KIRK P | England | 105 |
| 6 | LONGATTO A | Brazil | 14 | DIMMER KS | Germany | 98 |
| 7 | BECKER HM | BECKER HM | 10 | ULLAH MS | England | 97 |
| 8 | GRANJA S | Portugal | 9 | BROOKS GA | USA | 97 |
| 9 | IWANAGA T | Japan | 9 | PELLERIN L | Switzerland | 89 |
| 10 | LI Y | USA | 8 | WARBURG O | Germany | 82 |
Ranking of the frequency and centrality of keywords deprived from published articles on the research of MCT1 indexed in the Web of Science during 2008–2018.
| Rank | Frequency | Keywords | Centrality | Keywords |
|---|---|---|---|---|
| 1 | 224 | expression | 0.34 | glycolysis |
| 2 | 183 | MCT | 0.30 | cd147 |
| 3 | 149 | lactate | 0.26 | in vitro |
| 4 | 140 | metabolism | 0.22 | chain fatty acid |
| 5 | 119 | MCT1 | 0.19 | central nervous system |
| 6 | 90 | cell | 0.18 | immunohistochemistry |
| 7 | 79 | hypoxia | 0.16 | immunoglobulin superfamily |
| 8 | 71 | gene expression | 0.14 | localization |
| 9 | 69 | Cd147 | 0.14 | tumor |
| 10 | 69 | skeletal muscle | 0.13 | in vivo |
| 11 | 63 | glycolysis | 0.11 | MCT4 |
| 12 | 59 | in vitro | 0.11 | Multidrug resistance |
| 13 | 53 | cancer | 0.10 | hypoxia |
| 14 | 50 | Cancer cell | 0.10 | gene expression |
| 15 | 50 | rat | 0.10 | brain |
Figure 6Top 34 keywords with the strongest citation bursts on the research of MCT1 indexed in the Web of Science during 2008–2018.
The top 10 co-cited journals in MCT1 research.
| Rank | Co-Cited Journal | IF (2017) | Count |
|---|---|---|---|
| 1 | J BIOL CHEM | 4.010 | 545 |
| 2 | P NATL ACAD SCI USA | 9.504 | 398 |
| 3 | BIOCHEM J | 3.857 | 393 |
| 4 | CANCER RES | 9.13 | 328 |
| 5 | J PHYSIOL-LONDON | 4.540 | 308 |
| 6 | PLOS ONE | 2.766 | 296 |
| 7 | J CLIN INVEST | 13.251 | 285 |
| 8 | SCIENCE | 41.058 | 284 |
| 9 | NATURE | 41.577 | 252 |
| 10 | CELL | 31.398 | 252 |
The analysis of clusters.
| Cluster ID | Terms | Size | Sihouette | Mean (Year) |
|---|---|---|---|---|
| 0 | human tumor | 104 | 0.786 | 2012 |
| 1 | human tumor | 49 | 0.827 | 2006 |
| 2 | adaptive role line | 48 | 0.921 | 2005 |
| 3 | non-transformed intestinal epithelial cell l | 36 | 0.933 | 2008 |
| 4 | monocarboxylate transporter (MCT) | 36 | 0.933 | 2006 |
| 6 | prostate cancer drug resistance | 22 | 0.892 | 2006 |
| 5 | aerobic glycolysis | 21 | 0.99 | 2011 |
| 7 | intracellular site | 17 | 0.978 | 2005 |
| 10 | rat brain | 13 | 0.974 | 2005 |
| 12 | monocarboxylate cotransporter | 9 | 0.985 | 2002 |
| 15 | intestinal epithelial | 6 | 0.988 | 2003 |
The top 10 co-cited references in MCT1 research.
| Rank | Co-Cited Reference | Count | Main Findings |
|---|---|---|---|
| 1 | SONVEAUX P, 2008, J CLIN INVEST, V118, P3930 | 102 | MCT1 inhibition has clinical antitumor potential. |
| 2 | HALESTRAP AP, 2004, PFLUGERS ARCH, V447, P619 | 81 | An introduction to the SLC16 Gene Family. |
| 3 | HANAHAN D, 2011, CELL, V144, P646 | 68 | The hallmarks of cancer comprise six biological capabilities, which constitute an organizing principle for rationalizing the complexities of neoplastic disease. |
| 4 | HALESTRAP AP, 2012, IUBMB LIFE, V64, P1 | 61 | An introduction to the structure and functional characterization of the Monocarboxylate Transporter Family. |
| 5 | LE FR, 2011, P NATL ACAD SCI USA, V108, P16663 | 61 | African monkeys are infected by Plasmodium falciparum nonhuman primate-specific strains. |
| 6 | PINHEIRO C, 2012, J BIOENERG BIOMEMBR, V44, P127 | 60 | A literature review on the role of MCTs in cancer maintenance and aggressiveness in solid tumors in different locations. |
| 7 | HALESTRAP AP, 2012, IUBMB LIFE, V64, P109 | 57 | An introduction to the role and regulation of the Monocarboxylate Transporter Family. |
| 8 | ULLAH MS, 2006, J BIOL CHEM, V281, P9030 | 55 | The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. |
| 9 | HALESTRAP AP, 2013, MOL ASPECTS MED, V34, P337 | 51 | An introduction to the structure, role, and regulation of the Monocarboxylate Transporter Family in health and disease. |
| 10 | GALLAGHER SM, 2007, CANCER RES, V67, P4182 | 45 | Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. |
Figure 7Co-citation map (timeline view) of references from publications on MCT1 research.